Plus, rheumatology drug news from EULAR 2014
EULAR 2014: Non-Tumor Necrosis Factor Biologics Update
Clinical trials on rheumatology drugs, including sarilumab, show promise for patients with rheumatoid arthritis also taking methotrexate
EULAR 2014: Biosimilar Drug Production Raises Concerns
Rheumatology experts question biosimilars’ safety, efficacy given their complex production process
EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis
Latest findings on rheumatological drug therapies, including methotrexate for RA, tumor necrosis factor inhibitors for SpA
Is Shared Decision Making Possible in Rheumatology?
A rheumatologist voices skepticism that physicians, patients can arrive at mutually shared healthcare decisions
Rheumatology Advocacy Starts at Home
The ACR expands advocacy efforts to impact state legislatures, local organizations
Autoimmune Myelofibrosis: A Case Review
Diagnosis, treatment and management of AMF in Hispanic patient with lupus
Rheumatology Drug Updates, Trials, Safety Data
An update on baricitinib, plus safety warnings on belimumab,
eszopiclone and zoledronic acid
Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support
Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco outline disease classification criteria, treat-to-target approach to lupus
Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis
Physicians at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco report on studies about JAK inhibitors as targeted immunomodulators and disease-modifying therapies in RA
- « Previous Page
- 1
- …
- 106
- 107
- 108
- 109
- 110
- …
- 120
- Next Page »